Nanni C; Zamagni E; Cavo M; Rubello D; Tacchetti P; Pettinato C; Farsad M; Castellucci P; Ambrosini V; Montini GC; Al-Nahhas A; Franchi R; Fanti S., 11C-choline vs. 18F-FDG PET/CT in assessing bone involvement in patients with multiple myeloma., «WORLD JOURNAL OF SURGICAL ONCOLOGY», 2007, 5, pp. 68 - 68 [Scientific article]
C. Nanni; V. Ambrosini; E. Zamagni; M. Farsad; P. Castellucci; M. Sansovini; D. Rubello; G. Montini; M. Cavo; S. Fanti., Comparison between 18F-FDG PET/CT and 11C-Choline PET/CT for the evaluation of multiple myeloma, in: , «THE JOURNAL OF NUCLEAR MEDICINE», 2006, 47S, pp. 478p - 478p (atti di: SNM annual meeting,, 3-7 June,, San Diego, USA.) [Abstract]
Tosi P; Zamagni E; Cangini D; Tacchetti P; Perrone G; Ceccolini M; Baccarani M; Cavo M., Complete remission upon bortezomib-dexamethasone therapy in three heavily pretreated multiple myeloma patients relapsing after allogeneic stem cell transplantation., «ANNALS OF HEMATOLOGY», 2006, 85(8), pp. 549 - 551 [Scientific article]
Tosi P; Zamagni E; Cellini C; Parente R; Cangini D; Tacchetti P; Perrone G; Ceccolini M; Boni P; Tura S; Baccarani M; Cavo M., First-line therapy with thalidomide, dexamethasone and zoledronic acid decreases bone resorption markers in patients with multiple myeloma., «EUROPEAN JOURNAL OF HAEMATOLOGY», 2006, 76, pp. 399 - 404 [Scientific article]
Ambrosini V.; Farsad M.; Nanni C.; Schiavina R.; Rubello D.; Castellucci P.; Pasquini E.; Franchi R.; Cavo M.; Fanti S., Incidental finding of an (11)C-choline PET-positive solitary plasmacytoma lesion., «EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING», 2006, 33, pp. 1522 - 1522 [Scientific article]
Durie BG, Harousseau JL, Miguel JS, Blade J, Barlogie B, Anderson K, Gertz
M, Dimopoulos M, Westin J, Sonneveld P, Ludwig H, Gahrton G, Beksac M, Crowley
J, Belch A, Boccadaro M, Cavo M, Turesson I, Joshua D, Vesole D, Kyle R,
Alexanian R, Tricot G, Attal M, Merlini G, Powles R, Richardson P, Shimizu K,
Tosi P, Morgan G, Rajkumar SV;, International uniform response criteria for multiple myeloma., «LEUKEMIA», 2006, 20, pp. 1467 - 1473 [Scientific article]
Tosi P; Zamagni E; Cangini D; Tacchetti P; Di Raimondo F; Catalano L; D'ArcoA; Ronconi S; Cellini C; Offidani M; Perrone G; Ceccolini M; Brioli A; Tura S;Baccarani M; Cavo M., Osteonecrosis of the jaws in newly diagnosed multiple myeloma patients treatedwith zoledronic acid and thalidomide-dexamethasone., «BLOOD», 2006, 108, pp. 3951 - 3952 [Scientific article]
Cavo M; Terragna C; Renzulli M; Zamagni E; Tosi P; Testoni N; Nicci C; Cangini D; Tacchetti P; Grafone T; Cellini C; Ceccolini M; Perrone G; Martinelli G; Baccarani M; Guardigni L., Poor outcome with front-line autologous transplantation in t(4;14) multiple myeloma: low complete remission rate and short duration of remission., «JOURNAL OF CLINICAL ONCOLOGY», 2006, 24, pp. e4 - e5 [Scientific article]
Cavo M., Proteasome inhibitor bortezomib for the treatment of multiple myeloma., «LEUKEMIA», 2006, 20, pp. 1341 - 1352 [Scientific article]
Nanni C.; Zamagni E.; Farsad M.; Castellucci P.; Tosi P.; Cangini D.; Salizzoni E.; Canini R.; Cavo M.; Fanti S., Role of (18)F-FDG PET/CT in the assessment of bone involvement in newly diagnosed multiple myeloma: preliminary results., «EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING», 2006, 33(5), pp. 525 - 531 [Scientific article]
Cavo M; Baccarani M., The changing landscape of myeloma therapy., «THE NEW ENGLAND JOURNAL OF MEDICINE», 2006, 354, pp. 1076 - 1078 [Scientific article]
C. Nanni; V. Ambrosini; E. Zamagni; M. Farsad; P. Castellucci; M. Cavo; V. Allegri; C. Pettinato; G. Montini; S. Fanti., Use of 18 FDG PET/CT to evaluate therapy response of bone myelomatous lesions, in: , «THE JOURNAL OF NUCLEAR MEDICINE», 2006, 47S, pp. 52p - 52p (atti di: SNM annual meeting, 3-7 June, San Diego, USA) [Abstract]
Cavo M., Myeloma therapy: the future is bright, «BLOOD», 2005, 106, pp. 4018 - 4019 [Scientific article]
TOSI P; ZAMAGNI E; CELLINI C; PLASMATI R; CANGINI D; TACCHETTI P; PERRONE; G; PASTORELLI F; TURA S; BACCARANI M.; CAVO M., Neurological toxicity of long-term (>1 yr) thalidomide therapy in patients with multiple myeloma., «EUROPEAN JOURNAL OF HAEMATOLOGY», 2005, 74, pp. 212 - 216 [Scientific article]
CAVO M; ZAMAGNI E; TOSI P; TACCHETTI P; CELLINI C; CANGINI D; DE VIVO A; TESTONI N; NICCI C; TERRAGNA C; GRAFONE T; PERRONE G; CECCOLINI M; TURA S; BACCARANI M.; BOLOGNA STUDY., Superiority of thalidomide and dexamethasone over vincristine-doxorubicindexamethasone (VAD) as primary therapy in preparation for
autologous transplantation for multiple myeloma., «BLOOD», 2005, 106, pp. 35 - 39 [Scientific article]
